Ponatinib and blinatumomab without chemotherapy beat imatinib plus chemotherapy in Ph-positive ALL

Design

Phase 3, randomised (2:1) trial (GIMEMA ALL2820) with crossover for residual disease in the control arm

Population

236 adults with Philadelphia-positive ALL, median age 55 years

Primary outcome

Event-free survival

Effect

24-month event-free survival 86% vs 67% (P < 0.001); relapse incidence 5% vs 13%; overall survival 90% vs 85%

GIMEMA ALL2820 was a phase 3 trial that randomised 236 adults with Philadelphia-positive acute lymphoblastic leukaemia 2:1 to ponatinib plus blinatumomab (158) or imatinib plus chemotherapy (78) as frontline treatment. Median age was 55 years (range 24 to 82). Patients in the control group with persistent or returning measurable residual disease could cross over to the intervention. The primary end point was event-free survival.

At a median follow-up of 23.7 months, estimated 24-month event-free survival was 86% against 67% (P < 0.001), and survival free of measurable residual disease was 68% against 42%. Complete haematological response at the end of induction was 94% vs 79%, and molecular response after blinatumomab consolidation 71% vs 49%. After crossover, 20 of 31 patients (64%) achieved molecular response. Cumulative relapse incidence was 5% vs 13%, and overall survival 90% vs 85%. Only 19% of the intervention group had a transplant after first complete response.

The benefit is large for event-free survival, but follow-up is short, overall survival differences are small at this point, and the abstract does not report adverse events. Ponatinib carries vascular and hepatic risks and blinatumomab needs specialist infusion care. Access and cost in India are not addressed.

• Event-free survival at 24 months was 86% with ponatinib-blinatumomab vs 67% with imatinib-chemotherapy.
• Survival free of measurable residual disease was 68% vs 42%, and relapse incidence 5% vs 13%.
• Overall survival was 90% vs 85% at this follow-up.
• Only 19% of the intervention group went to transplant in first response.
• Consider this approach in fit adults at specialist centres, with attention to the safety profile of both drugs.

Why it matters

It suggests that the standard backbone of chemotherapy can be dropped in this leukaemia while improving outcomes.

Don't overread it

Follow-up is under two years, the overall survival difference is small and toxicity data are not in the abstract.

The statistics, in plain English

Event-free survival counts relapse, progression or death as events. The 19-point difference at two years is large, but overall survival has not yet separated clearly (90% vs 85%), partly because the control group could cross over and be rescued. Longer follow-up will show whether the early benefit holds.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.